Exelixis Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Exelixis Inc 's ROA in the third quarter of 2026?
Exelixis Inc achieved a return on average assets (ROA) of 63.74 % in its third quarter of 2026, this is above EXEL's average return on assets of 7.33%.
Exelixis Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROA decreased relative to the period ending Jul 03 2026, due to the decline in net income.

However, within the Healthcare sector 14 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Oct 02 2026 quarter, so far to 48, from total ROA ranking in the second quarter of 2026 at 69.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Oct 02 2026) III. Quarter	(Jul 03 2026) II. Quarter	(Apr 03 2026) I. Quarter	(Jan 02 2026) IV. Quarter	(Oct 03 2025) III. Quarter
Y / Y Total Assets Change	-10.63 %	-6.4 %	-8.59 %	12.47 %	8.42 %
Y / Y Net Income Change	-51.1 %	14.32 %	30.89 %	53.16 %	63.53 %
Net Income (TTM) in million	1,668	1,896	1,837	1,724	1,551
Return On Assets (TTM)	63.74 %	70.43 %	67.15 %	61.66 %	57.09 %
EXEL's Total Ranking	# 48	# 69	# 69	# 78	# 83
Total Assets (TTM) in million	2,523	2,507	2,594	2,844	2,824
Seq. Total Assets Change	0.66 %	-3.35 %	-8.82 %	0.74 %	5.43 %
Seq. Net Income Change	-54.06 %	-0.72 %	-3.83 %	11.49 %	7.4 %

EXEL's 5 Years Annual ROA >> Back to EXEL Management Effectiveness >> Compare EXEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 5
Sector	# 15
Overall	# 46

Return On Assets Statistics
High	Average	Low
70.51 %	7.33 %	-65.11 %
(Jul 03 2026)		(Jan 02 2015)

Financial Statements
Exelixis Inc 's Assets	$ 2,523 million	EXEL's Balance sheet
Exelixis Inc 's Income	$ 218 million	Quarterly EXEL's Income Statement
EXEL's Income by Division		See EXEL's Income by Division

Annual Return On Assets	(Jan 02 2026) FY 2025	(Jan 03 2025) FY 2024	(Dec 29 2023) FY 2023	(Dec 30 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	36.34 %	-2.13 %	-9.1 %	13.41 %	26.42 %
Total Assets in million	3,448	2,529	2,584	2,843	2,507
Y / Y Net Income Change	43.3 %	158.53 %	11.68 %	-20.67 %	369.86 %
Net Income in million	1,724	1,203	465	417	525
Annual Return On Assets	49.99 %	47.57 %	18.01 %	14.66 %	20.95 %

EXEL's 5 Years Annual ROA >> Back to EXEL Management Effectiveness >> Compare EXEL ROA to its Competitors

Comment on EXEL's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 49.99 % compared to prior year, due to annual net income growth of 43.3 % to $1,723.78 million, while value of Exelixis Inc 's overall assets grew just by 36.34 % to $3,448.03 million, compared to $3,448.03 a year before.

More Return On Assets Ratios
EXEL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EXEL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EXEL's Competitors
Subscribers only: Roa for Exelixis Inc 's Suppliers
Subscribers only: Return On Assets for EXEL's Customers

You may also want to know
EXEL's Roi	EXEL's Inventory Turnover Ratio	EXEL's Growth Rates	EXEL's Dividend Comparisons
	EXEL's Profitability Ratios	EXEL's Asset Turnover Ratio	EXEL's Dividend Growth
EXEL's Roe	EXEL's Valuation Ratios	EXEL's Financial Strength Ratios	EXEL's Dividend Payout Ratio

Companies with similar Return On Assets at Oct 02 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-10-30T16:59:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.